Protagonist Therapeutics (PTGX) CMO exercises options, sells 15,000 shares

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.

Insider Trade Summary

Net Seller: 15,000 shares ($1,571,850)

Net Sell 3 txns

Insider MOLINA ARTURO MD

Role Chief Medical Officer

Sold 15,000 shs ($1.57M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	15,000	$0.00	--
Exercise	Common Stock	15,000	$8.04	$121K
Sale	Common Stock	15,000	$104.79	$1.57M

Holdings After Transaction: Stock Option (right to buy) — 50,971 shares (Direct); Common Stock — 99,115 shares (Direct)

Footnotes (1)

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOLINA ARTURO MD

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2026		M		15,000	A	$8.04	99,115	D
Common Stock	03/26/2026		S		15,000	D	$104.79(1)	84,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.04	03/26/2026		M			15,000	(2)	11/15/2032	Common Stock	15,000	$0.00	50,971	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer.

	/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PTGX’s Chief Medical Officer report?

Arturo Molina reported exercising options for 15,000 PTGX shares and selling 15,000 shares the same day. This exercise-and-sell pattern converts option value into cash while maintaining a remaining direct holding in the company’s common stock.

At what prices did Arturo Molina exercise and sell PTGX shares?

He exercised stock options at an exercise price of $8.04 per share and sold 15,000 PTGX common shares at a weighted average price of $104.79. The sale occurred in multiple trades between $103.99 and $105.54, according to the disclosure.

How many Protagonist Therapeutics (PTGX) shares does Arturo Molina hold after the Form 4?

After the reported transactions, Arturo Molina directly holds 84,115 shares of PTGX common stock. This figure reflects his position following both the option exercise that increased his holdings and the subsequent sale that reduced them by the same 15,000 shares.

What stock option grant is related to Arturo Molina’s PTGX Form 4 filing?

The option exercised was granted on November 7, 2022. One quarter vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to his continued service with Protagonist Therapeutics.

Was Arturo Molina’s PTGX stock sale done in multiple trades?

Yes. The filing states the 15,000 PTGX shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. The reported $104.79 figure is a weighted average sale price across those individual trades.

Does the PTGX Form 4 show remaining unexercised options for Arturo Molina?

The summary of derivative holdings in the disclosure is empty, indicating no additional derivative positions are listed there. The reported transaction involved exercising 15,000 options from a grant that continues vesting through November 7, 2026, under stated conditions.